Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
更正:评估口服福瑞替尼(GSK1363089,一种cMET/VEGFR2抑制剂)两种给药方案治疗转移性胃癌患者的II期研究
期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0276211
Shah, Manish A; Wainberg, Zev A; Catenacci, Daniel V T; Hochster, Howard S; Ford, James; Kunz, Pamela; Lee, Fa-Chyi; Kallender, Howard; Cecchi, Fabiola; Rabe, Daniel C; Keer, Harold; Martin, Anne-Marie; Liu, Yuan; Gagnon, Robert; Bonate, Peter; Liu, Li; Gilmer, Tona; Bottaro, Donald P